Skip to main content
PLOS Mental Health logoLink to PLOS Mental Health
. 2026 Nov 10;3(11):e0000731. doi: 10.1371/journal.pmen.0000731

Long-acting injectable antipsychotics linked to reduced short-term disruptive life event and death

Bing Han 1,‡,*, Rebecca Butler 1, Karen J Coleman 1,2, Rebecca C Rossom 3, Xia Li 1, Heidi C Waters 4, Claudia L Nau 1,2
Editor: Karli Montague-Cardoso5
PMCID: PMC13750607  PMID: 43008062

Abstract

Long-acting injectable antipsychotics (LAI) may be beneficial for patients with schizophrenia (SCZ) or bipolar I disorder (BPI) compared with oral antipsychotics. We aimed to assess the association of LAI use on all-cause mortality and disruptive life events (DLE) among patients recently diagnosed with SCZ or BPI. We conducted a retrospective cohort study using adult patients meeting study eligibility criteria in Kaiser Permanente Southern California (KPSC) during 2007–2019. The index event for cohort entry was the first mental health related emergency department or inpatient encounter after initial diagnosis of SCZ or BPI. Two study arms were defined by the medication history within 180 days after index events: received LAI (LAI arm) and received oral antipsychotics only (oral-only arm). Unadjusted and adjusted two-sample comparisons were performed, where adjusted analyses used propensity score matching to balance observed characteristics. Outcomes were occurrence of specific DLEs (arrests, bankruptcy, and judgment filings), occurrence of any DLE, and all-cause mortality during the year after index events. The cohort had 3,667 patients in the oral-only arm and 218 in the LAI arm. Compared with the oral-only arm, the LAI arm had lower risks in all outcomes qualitatively. The rarity of the outcome and limited sample size in the LAI arm limited statistical power: adjusted risk difference was -1.68% for occurrences of any DLE (95% CI: -3.44%, 0.08%, p < 0.10), and -0.46% for all-cause mortality (95% CI: -0.98%, 0.06%, p < 0.10). Patients with SCZ or BPI taking LAIs may be associated with lower risk of DLE and mortality within the one-year period after index than those who took oral antipsychotics only. Larger studies are needed to further confirm these associations.

Introduction

Schizophrenia (SCZ) and bipolar I disorder (BPI) are severe mental illnesses. Patients with diagnoses of SCZ or BPI often have recurring mental health related emergency room visits and hospital stays [1,2]. They also have an increased risk of experiencing disruptive life events (DLE) such as contact with the criminal legal system and financial difficulties [3–6] and increased risk of mortality and disability [7]. Antipsychotic medication is a key element of treating SCZ and BPI. Adherence to antipsychotic medications has shown to prevent relapse of psychotic episodes and re-hospitalizations and to reduce suicide and overall mortality [8,9].

However, adherence to oral antipsychotics has been historically and persistently low [10,11]. Low adherence rates have been attributed to the strong side effects of antipsychotics and other common challenges with medication adherence among patients with severe chronic illnesses, such as building a daily routine and managing complex treatment regiments [12,13]. In response to challenges with adherence, long-acting injectable antipsychotic medications (LAIs) have been developed [13]. Several studies have shown that LAIs are more effective than oral medications at improving adherence and reducing negative consequences of nonadherence [14–17]. While LAIs may provide some advantage over oral antipsychotic medications in terms of their stability of serum levels, overall side effects are likely comparable to other antipsychotic medications [18]. LAIs in the U.S. and Canada have traditionally been used as second line treatments for patients who have been struggling with relapse and non-adherence to oral treatments [13,19]. A relatively small study identified some unfavorable perceptions of LAIs, including concerns regarding their coercive image; however, these findings may not be generalizable to broader patient and provider populations [20].

A possible pathway linking LAI use to mortality and DLEs is through improved antipsychotic medication adherence. Improved adherence may reduce relapse and psychiatric destabilization and thereby potentially reduce the risk of downstream adverse outcomes. Some research suggests that use of LAIs may reduce the risk of suicide and all-cause mortality [21–23]. However, evidence is limited. Information on the effect of LAIs on DLEs, such as arrest and bankruptcy, is not available in the literature to our knowledge.

Our goal was to empirically investigate whether LAI use was associated with lower rates of DLEs and mortality during the 12 months following a first mental health crisis, defined as a mental health-related emergency department (ED) visit or hospitalization, among patients with SCZ or BPI. DLEs and mortality are complex outcomes influenced by many determinants beyond antipsychotic medication. This exploratory study did not intend to establish a causal mechanism but rather to provide empirical evidence that may inform future investigations of the potential mechanisms. Toward this goal, we used electronic health records (EHR) data from a large integrated health care system, Kaiser Permanente Southern California (KPSC), to identify patients with first diagnoses of SCZ or BPI at KPSC during 2007–2019. DLEs included arrest, judgement, and bankruptcy filing, which were retrieved from publicly available data warehoused by TransUnion [6]. All-cause mortality data were from KPSC’s EHR and the National Death Index.

Methods

Cohort of new patients with SCZ or BMI

KPSC is the largest health care provider in southern California with 4.8 million members in a 9-county area. KPSC’s members are approximately representative of the general population it serves in terms of demographic characteristics [24]. We identified diagnoses of SCZ using International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 295.0 through 295.9, 297.1, 297.3, 298.8, or 298.9; International Statistical Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes F20.x, F22-25, F28-F29. We identified diagnoses of BPI by ICD-9-CM codes 296.0x, 296.1x, 296.4x, 296.5x, 296.6x, 296.7x, 296.8x, excluding 296.82, and ICD-10-CM codes F30.x, F31.x, excluding F31.81. We required two outpatient diagnoses or one inpatient diagnosis to establish a qualifying diagnosis of SCZ or BPI. A newly diagnosed case was defined as a patient who had at least 12 months of KPSC membership (allowing for a maximum gap of 30 days in insurance coverage) prior to their first qualifying diagnosis between 2007 and 2019. To address potential confounding by disease severity and prognosis, we identified newly diagnosed cases at their first mental health related ED or inpatient encounter. Mental health related health care encounter included mental health diagnosis and other diagnoses that may be mental health related such as vertigo or dehydration. The index event was defined as the first mental health related inpatient or ED encounter. The index event and the first qualifying diagnosis could be during the same health care encounter.

Eligibility criteria included being between 18 and 65 years old, inclusive, at the time of index event (Fig 1). Patients who did not have a minimum of one-year follow-up period after the index event, those that had an LAI before the index event (i.e., were not LAI naïve), and those that did not receive any form of medication during the 180-day window after the index event were excluded.

Fig 1. CONSORT diagram for the study cohort.

Fig 1

Exposure and study arms

In this empirical study, the exposure of interest was having at least one LAI administered within the 180-day window after the index event, regardless of concurrent oral antipsychotic use. The comparison group consisted of patients who received oral antipsychotic treatment but no LAI during this period. Thus, the exposure comparison was between LAI receipt, with or without concurrent oral treatment, and oral treatment without LAI receipt. We chose a relatively long window of 180 days to define the LAI exposure, since LAIs often require stabilization on the oral form of the medicine prior to the LAI administration or may not be the first choice of medication following an emergency encounter. The 180-day exposure period also yielded a slightly larger sample size for statistical analysis. The study cohort was divided into two mutually exclusive arms based on the antipsychotic medication history during the exposure period. The oral-only arm consisted of 3,667 eligible patients who received only oral antipsychotic medications and did not receive any LAI during the exposure period. The LAI arm received an LAI during the exposure period. Since LAIs were rarely prescribed as first line treatment, patients in the LAI arm often also received oral antipsychotic medications during the exposure period.

Study outcomes and covariates

Data on all-cause mortality came from KPSC’s EHR and the national death index. Patients’ demographic characteristics, health care encounter history, and medication history were also from KPSC’s EHR. Data on DLEs including arrests, judgement, and bankruptcy filings were from TransUnion and have been described prior [6]. Records of DLE were publicly available court and police records and were assembled and warehoused by TransUnion, which did not include credit reports, credit scores, or other nonpublic financial information. More than 98% of eligible patients were linked to the TransUnion data. A multistep data-transfer process separated identifying information from clinical information, and the linked analytic data were de-identified and maintained on secure, firewalled, and encrypted servers. Linkages between the public data and EHR at the patient level were described in details in a prior study [6].

Since DLEs were rare, we defined three dichotomous outcomes as whether a specific type of DLE (arrest, bankruptcy, and judgement filing) ever occurred during the one-year period after the index event. We also defined a composite outcome of any of the three types of DLE occurrence during the 1-year study period. All-cause mortality instance during the study period was defined as the fourth binary outcome.

Statistical analysis

We calculated descriptive statistics for the full study cohort and by study arms. Due to the rarity of all outcomes, we could not use logistic regression models for our analysis. Instead, we used two-sample comparisons of the risk of each study outcome. First, we conducted unadjusted two-sample comparisons between the LAI and the oral-only study arms. For each study outcome, we estimated the risk difference (RD) and the relative risk (RR). RD assessed the observed difference in risk of experiencing an outcome between the LAI arm and the oral-only arm as percentage points, where a negative value indicated a reduction of risk and a positive value indicated an increase in risk associated with LAI. RR calculated the ratio of risk between the LAI arm and the oral-only arm, where a value smaller than one indicated a reduced risk of experiencing the outcome of interest associated with LAIs and a value greater than one indicated an increased risk of experiencing the outcome of interest associated with LAIs. Next, we conducted adjusted analyses using propensity score matching, which was a semiparametric covariate adjustment technique [25,26]. We used a 3-to-1 matching ratio between oral-only and LAI patients. Matching dimensions included sex, race/ethnicity, age at index events, and primary diagnosis (SCZ vs. BPI). The calendar year of index events was also included in the propensity score to adjust for potential secular trends or unobserved time-varying effects potentially confounded with the outcomes [27]. The propensity score matching procedure was conducted using library(MatchIt) in R 4.3.1 without replacement. Covariate balances in the matched sample were assessed using standardized mean differences (SMD). Sensitivity analysis was performed to control for the 3-to-1 matching clusters in RD estimates. Wherever applicable, we applied the Farring-Manning score method to slightly increase statistical efficiency than the standard Wald’s z-test [28,29].

Because this study was exploratory, we reported p-values below 0.10 in addition to the conventional threshold of 0.05 and 0.01 [30,31]. Results with 0.05 < p-value<0.10 were not interpreted as statistically significant but were considered as weak signals for future hypothesis generation. Interpretation of these results focused primarily on the magnitude and precision of the estimates, as reflected by the point estimates and 95% confidence intervals.

All unadjusted and adjusted analyses were conducted in SAS 9.4. Transunion and KPSC EHR data retrieval started on 01/11/2020 (November 1st, 2020) and finalized (person-level linking and validation) on 11/04/2023 (April 11, 2023).

Results

Participants

Table 1 presents the descriptive statistics of the study cohort. Most patients were in the oral-only arm (n = 3,667; 94.4%). In the LAI arm (n = 218), most patients (89.0%) also received oral antipsychotic medications during the exposure period, i.e., the 180-day window after the index event. The majority of study patients were male (62.4%), with the LAI arm having a higher proportion of males than the oral -only arm (76.6% vs. 61.6%). The patient cohort was young, around 21.7 years old (SD = 3.2) at the initial qualifying diagnosis and 22.1 years old (SD = 3.3) at the index event with little to no difference between the two study arms. The study sample was racially and ethnically diverse. The majority of oral-only arm was Latino (39.1%) or white (34.1%), while a smaller proportion were African American (17.1%) or identified with another race or ethnicity (9.8%). Patients in the LAI arm predominantly identified as Latino (32.6%) or white (30.3%) and had notably higher representation of African Americans (25.2%) and patients who identified with another race or ethnicity (11.9%) than the oral-only arm. There were slightly more patients with SCZ than patients with BPI in the oral-only arm (52.5% vs. 47.5%). By contrast, most patients in the LAI arm had SCZ (77.5% vs. 22.5%). Overall, about 8% patients in both arms were insured by Medicaid. During the 180-day exposure period, patients were covered by oral antipsychotic medications for an average of 103.6 days (SD = 59.0) with little difference between the two arms. Patients in the LAI arm received an average of 59.2 days or LAI coverage (SD = 46.2).

Table 1. Study sample descriptives statistics and balance assessment between study arms. The “oral-only” and “LAI” columns are for the two study arms, respectively. The “matched oral-only” column is the subsample of the oral-only arm matched to the LAI patients by 3:1 propensity score matching. The two “SMD” columns report the standardize mean differences before and after matching.

Characteristics a Overall

N = 3,885
Oral-only

N = 3,667
LAI

N = 218
Matched oral-only

N = 654
SMD b

LAI vs. oral-only
SMD b

LAI vs.

matched oral-only
Gender
Male 2,425 (62.4) 2,258 (61.6) 167 (76.6) 507 (77.5) 0.36 0.02
Female 1,460 (37.6) 1,409 (38.4) 51 (23.4) 147 (22.5) -0.36 -0.02
Age at initial diagnosis c 21.7 (3.2) 21.7 (3.2) 21.3 (3.0) 21.2 (2.8) -0.08 0.04
Age at index event 22.1 (3.3) 22.1 (3.3) 21.7 (2.9) 21.6 (2.7) -0.16 0.03
Race/ethnicity
Hispanic 1,503 (38.7) 1,432 (39.1) 71 (32.6) 223 (34.1) -0.14 -0.03
White 1,315 (33.8) 1,249 (34.1) 66 (30.3) 187 (28.6) -0.08 0.04
Black 682 (17.6) 627 (17.1) 55 (25.2) 172 (26.3) 0.19 -0.02
Other 385 (9.9) 359 (9.8) 26 (11.9) 72 (11.0) 0.07 0.03
Primary diagnosis
SCZ 2,093 (53.9) 1,924 (52.5) 169 (77.5) 501 (76.6) -0.60 0.02
BPI 1,792 (46.1) 1,743 (47.5) 49 (22.5) 153 (23.4) 0.60 -0.02
Year of index event 2014 (3) 2014 (3) 2014 (3) 2014 (3) 0 0
Had oral antipsychotics in 180 days after index eventsc 3,861 (99.4) 3,667 (100) 194 (89.0) 654 (100) -0.35 -0.35
Medicaid c 320 (8.2) 302 (8.2) 18 (8.3) 51 (7.8) 0.00 0.02
# Days under antipsychotic medications during the 180-day exposure windowc
Oral 103.6 (59.0) 103.4 (58.9) 106.9 (61.4) 103.2 (58.6) 0.06 0.06
LAI 59.2 (46.2)

an(%) for categorical variables and mean (SD) for numerical variables.

bStandardized mean differences.

cNot a matching dimension.

Table 1 also reported the characteristics of the subsample after the 3-to-1 propensity score matching procedure. Covariate balance on sex, race/ethnicity, and primary diagnosis was substantially improved after matching. Absolute SMDs for all balancing covariates were below 0.10 after matching.

Disruptive life events and mortality

Table 2 presents the results of unadjusted two-sample analysis between the LAI and oral-only arms prior to propensity score matching. The prevalence rates of all study outcomes were lower in the LAI arm compared to the oral-only arm, with only 2 total outcomes of interest for the LAI arm (one arrest and one judgement filing). Prior to matching, compared to the oral-only arm, the LAI arm had significantly lower risks for all-cause mortality (RD = -0.65%, 95% CI: -0.92% to -0.39%, p < 0.001) and bankruptcy (RD = -0.60%, 95% CI: -0.85% to -0.35%, p < 0.001). A weak signal was also observed for a lower risk of any DLE in the LAI arm (RD = -1.29%, 95% CI: -2.64% to 0.06%, p < 0.10). RR estimates for all outcomes were less than one, indicating reduced risk associated with LAIs but none of the RRs was statistically significant.

Table 2. Unadjusted analyses for binary study outcomes during 1-year follow-up since the index event between the LAI and oral-only arms.

Outcomes Oral-only (N = 3,667)

n(%)
LAI (N = 218)

n(%)
RD (%) a

(95% CI)
RRa

(95% CI)
Simple outcome
All-cause death 24 (0.65) 0 (0) -0.65 (-0.92, -0.39)*** 0 (0, 2.65)
Arrest 32 (0.87) 1 (0.46) -0.41 (-1.36, 0.53) 0.52 (0.09, 3.00)
Bankruptcy 22 (0.60) 0 (0) -0.60 (-0.85, -0.35)*** 0 (0, 2.89)
Judgment 30 (0.82) 1 (0.46) -0.36 (-1.30, 0.58) 0.56 (0.10, 3.20)
Composite outcome
Any DLE 81 (2.21) 2 (0.92) -1.29 (-2.64, 0.06) & 0.42 (0.11, 1.51)

aRD is risk difference between LAI and oral-only arms. RR is relative risk between LAI and oral-only arms. Statistical significance level is marked as p-value < 0.001 ***, <0.01 **, <0.05 *, <0.10 &.

Table 3 presents the adjusted analysis between the LAI arm and the matched oral-only arm (n = 654 after matching). Point estimates of RD and RR favored the LAI arm across all outcomes. However, statistical precision was generally weak due to the low number of outcomes of interest and the reduced sample size (Table 3). No estimate was statistically significant by the conventional p < 0.05 level. All-cause mortality had negative RD (adjusted estimate = -0.46%, 95% CI: -0.98% to 0.06%, p < 0.10). Bankruptcy had negative RD (estimate = -0.46%, 95% CI: -0.98% to -0.06%, p < 0.10). The composite outcome of any DLE also had negative RD (estimate = -1.68%, 95% CI: -3.44% to 0.08%, p < 0.10). Sensitivity analyses that further adjusted matching clusters gave very similar RD estimates and were hence omitted. All RR estimates were smaller than one, but all p-values exceeded 0.10.

Table 3. Adjusted analyses for binary DLE outcomes during 1-year follow-up since the index event between LAI and matched oral-only patients.

Outcomes Matched

(N = 654), n(%)
LAI

(N = 218), n(%)
RD (%) a

(95% CI)
RRa

(95% CI)
Simple outcome
All-cause death 3 (0.46) 0 (0) -0.46 (-0.98,0.06)& 0 (0, 3.82)
Arrest 6 (0.92) 1 (0.46) -0.46 (-1.62,0.70) 0.50 (0.08, 3.13)
Bankruptcy 3 (0.46) 0 (0) -0.46 (-0.98,0.06)& 0 (0, 3.82)
Judgment 8 (1.22) 1 (0.46) -0.76 (-2.00,0.47) 0.38 (0.06, 2.28)
Composite outcome
Any DLE 17 (2.60) 2 (0.92) -1.68 (-3.44,0.08)& 0.35 (0.09, 1.35)

aRD is risk difference between LAI and oral-only arms. RR is relative risk between LAI and oral-only arms. Statistical significance level is marked as p-value < 0.001 ***, <0.01 **, <0.05 *, <0.10 &.

Discussion

This retrospective cohort study linked KPSC’s EHR data to credit reporting agency data to compare the risk of DLE and mortality outcomes between patients who received LAIs or oral antipsychotics only after their first mental health related ED or inpatient visit (index event) following a recent diagnosis of BPI or SCZ. Findings indicated a trend of patients who received LAIs having lower risk of experiencing all-cause mortality, bankruptcy, or any DLE in the year following a mental health inpatient or ED visit, although the risk difference was less than 2% and did not reach statistical significance (p < 0.10 after propensity score adjustment). These findings also should be interpreted with caution as there were only two instances of outcomes in the LAI arm, one arrest and one judgement filing.

Despite the inability to draw strong conclusions comparing outcomes of LAIs and oral antipsychotics, this study has some important learnings. To our knowledge, this is the first paper assessing DLE outcomes of treated patients with serious mental illness. Prior research has shown that patients with SCZ and BPI have higher rates of DLEs compared to patients with major depressive disorder or the general population [6]. From a clinical perspective, the results of this study indicate that treating patients with SCZ and BPI with LAIs may be beneficial. Prior studies have shown that antipsychotics reduce all-cause mortality in patients with schizophrenia [32,33] and that LAIs are more effective than oral antipsychotics in this regard [34–36]. Our findings seem to support these prior studies. Future confirmative research is warranted.

The population of our study was also young, with a mean age of 22 years old. Research has shown that treating patients with SCZ and BPI early in the disease course is critically important [37]. Delay to first time treatment has been associated with higher levels of depression, and higher number of episodes [38]. The low number clinical outcomes of interest in this study may be due to the fact that our population was young and was treated early in the disease course, preventing further decline. It is also possible that the DLEs of interest were not likely to occur in a population of this age. Future studies of a more diverse age range are warranted.

The primary limitation to the internal validity of this study is its observational design. Without randomized treatment allocation, patients who received an LAI may have differed systematically from those who received oral antipsychotics only. Propensity-score matching improved balance only in the measured characteristics included in the model and could not address unmeasured confounding. In particular, limited or unavailable information on illness severity, socioeconomic status, prior medication adherence, and certain clinical comorbidities may have resulted in residual confounding. Second, the small LAI sample and sparse outcomes substantially reduced statistical power and precision, limited the inferential methods that could be reliably applied, and precluded sensitivity analyses using more nuanced exposure categories. Third, LAI exposure was defined without accounting for formulation, timing, duration, or continuity, and patients classified as most LAI recipients also received oral antipsychotics. The observed associations therefore cannot be solely attributed to LAI therapy. Fourth, the validity and completeness of the DLE were subject to limitations in the underlying public records and their aggregation by third-party vendors. Data availability may have varied across sources and over time, and the absence of a recorded event did not necessarily indicate that the event had not occurred. Although linking public legal and financial records with health records may raise privacy concerns, this study used only publicly available information and followed established procedures to protect patient confidentiality and ensure the ethical use of the linked data. Fifth, the one-year follow-up did not permit evaluation of the longer-term benefits or potential harms of LAI or oral antipsychotic treatment. Finally, this retrospective study did not include patient-reported experiences, treatment preferences, or perceptions of LAI treatment and therefore could not provide a comprehensive assessment of its potential benefits and burdens from the patient perspective.

Due to these limitations, particularly the potential for residual confounding, our findings cannot be interpreted as establishing any causal pathway. Although improved continuity of treatment and medication adherence may represent one possible pathway linking LAI use to DLEs, adherence and the intermediate clinical and social mechanisms underlying this association were not directly evaluated. Future study needs to elucidate the causal pathways that may be driving our results.

There were also several limitations that may restrict external generalizability. The patient population was relatively young and was drawn exclusively from a large integrated health system in Southern California. Treatment patterns and care coordination of patients may be different in an integrated setting than in other healthcare settings. There was also a very low proportion of patients covered by Medicaid in the study sample, and therefore may not be representative of the overall populations of patients with the SCZ or BPI conditions.

Conclusion

In this exploratory study, receipt of an LAI was associated with lower observed rates of some DLE and mortality outcomes compared with receiving only oral antipsychotic medication without an LAI. However, the small LAI group, sparse outcome events, wide confidence intervals, and potential residual confounding substantially limit the interpretation of these findings. The results should be considered hypothesis-generating and require confirmation in larger studies.

Acknowledgments

This study was funded by Otsuka Pharmaceutical Development & Commercialization and Lundbeck. The funders were included in discussions on the study design, results and reviewed the final manuscript and met authorship criteria. Funding was provided for data acquisition and study support. The authors were responsible for all final decisions. Funders did not have influence that could be considered undue or influenced the direction of the analysis.

Previous presentation: HCSRN Annual conference, Milwaukee, WI, April 2024

Data Availability

The individual-level data underlying this study cannot be made publicly available because they contain protected health information and are subject to institutional and third-party data-use agreements that prohibit public disclosure. Qualified researchers may request access to the data. Access is subject to institutional review, approval of the proposed use, and execution of applicable data-use agreements. Kaiser Permanente Southern California Institutional Review Board (https://kpscnursingresearch.org/kpsc-institutional-review-board-irb/) can be contacted by email (Regina.M.Valdez@kp.org).

Funding Statement

This study was funded by Otsuka Pharmaceutical Development & Commercialization and Lundbeck. Otsuka Pharmaceutical Development & Commercialization and Lundbeck provided support in the form of salaries through the research institution for the authors BH and CN, as well as funding for data acquisition and study support. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders were included in discussions on the study design, results, and reviewed the final manuscript. The authors were responsible for all final decisions. The other support was the salary of authors’ respective research institutions for RB, KC, RR, and XL.

References

  • 1.de Zelicourt M, Dardennes R, Verdoux H, Gandhi G, Khoshnood B, Chomette E, et al. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. Pharmacoeconomics. 2003;21(15):1081–90. doi: 10.2165/00019053-200321150-00002 [DOI] [PubMed] [Google Scholar]
  • 2.Puntis S, Minichino A, De Crescenzo F, Harrison R, Cipriani A, Lennox B. Specialised early intervention teams for recent-onset psychosis: a Cochrane Review. BJPsych Adv. 2022;28(3):136–136. doi: 10.1192/bja.2022.11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Drake RE. Employment and Schizophrenia: Three Innovative Research Approaches. Schizophr Bull. 2017;44(1):20–1. doi: 10.1093/schbul/sbx170 [DOI] [Google Scholar]
  • 4.Jin H, Mosweu I. The Societal Cost of Schizophrenia: A Systematic Review. Pharmacoeconomics. 2017;35(1):25–42. doi: 10.1007/s40273-016-0444-6 [DOI] [PubMed] [Google Scholar]
  • 5.Carmona VR, Gómez-Benito J, Huedo-Medina TB, Rojo JE. Employment outcomes for people with schizophrenia spectrum disorder: A meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 2017;30(3):345–66. doi: 10.13075/ijomeh.1896.01074 [DOI] [PubMed] [Google Scholar]
  • 6.Nau CL, Braciszewski JM, Rossom RC, Penfold RB, Coleman KJ, Simon GE, et al. Assessment of Disruptive Life Events for Individuals Diagnosed With Schizophrenia or Bipolar I Disorder Using Data From a Consumer Credit Reporting Agency. JAMA Psychiatry. 2023;80(7):710–7. doi: 10.1001/jamapsychiatry.2023.1179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Carr VJ, Lewin TJ, Neil AL, Halpin SA, Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. Br J Psychiatry. 2004;184:517–25. doi: 10.1192/bjp.184.6.517 [DOI] [PubMed] [Google Scholar]
  • 8.Cooper RE, Hanratty É, Morant N, Moncrieff J. Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLoS One. 2019;14(6):e0218711. doi: 10.1371/journal.pone.0218711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Warriach ZI, Sanchez-Gonzalez MA, Ferrer GF. Suicidal Behavior and Medication Adherence in Schizophrenic Patients. Cureus. 2021;13(1):e12473. doi: 10.7759/cureus.12473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–90. doi: 10.1034/j.1600-0447.2002.02437.x [DOI] [PubMed] [Google Scholar]
  • 11.Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. CNS Drugs. 2020;34(6):579–98. doi: 10.1007/s40263-020-00713-9 [DOI] [PubMed] [Google Scholar]
  • 12.Kozuki Y, Schepp KG. Adherence and nonadherence to antipsychotic medications. Issues Ment Health Nurs. 2005;26(4):379–96. doi: 10.1080/01612840590922425 [DOI] [PubMed] [Google Scholar]
  • 13.Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015;21(9):754–68. doi: 10.18553/jmcp.2015.21.9.754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lieslehto J, Tiihonen J, Lähteenvuo M, Tanskanen A, Taipale H. Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia. Schizophr Bull. 2022;48(3):655–63. doi: 10.1093/schbul/sbac014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Montemagni C, Del Favero E, Cocuzza E, Vischia F, Rocca P. Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study. Ther Adv Psychopharmacol. 2022;12:20451253221122526. doi: 10.1177/20451253221122526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Thaman P, Kulig CE, Greer D. Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. J Clin Psychopharmacol. 2024;44(2):96–9. doi: 10.1097/JCP.0000000000001810 [DOI] [PubMed] [Google Scholar]
  • 17.Devrımcı Özgüven H, Kir Y. Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder. Noro Psikiyatr Ars. 2021;58(Suppl 1):S47–52. doi: 10.29399/npa.27480 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Patel MX, Bent-Ennakhil N, Sapin C, di Nicola S, Loze J-Y, Nylander A-G, et al. Attitudes of European physicians towards the use of long-acting injectable antipsychotics. BMC Psychiatry. 2020;20(1):123. doi: 10.1186/s12888-020-02530-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.McKee KA, Crocker CE, Dikaios K, Otter N, Bardell A, Roy M-A, et al. Short communication: Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis. J Psychiatr Res. 2023;165:77–82. doi: 10.1016/j.jpsychires.2023.07.005 [DOI] [PubMed] [Google Scholar]
  • 20.Iyer S, Banks N, Roy M-A, Tibbo P, Williams R, Manchanda R, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives. Can J Psychiatry. 2013;58(5 Suppl 1):14S–22S. doi: 10.1177/088740341305805s03 [DOI] [PubMed] [Google Scholar]
  • 21.Haddad PM, Correll CU. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opin Pharmacother. 2023;24(4):473–93. doi: 10.1080/14656566.2023.2181073 [DOI] [PubMed] [Google Scholar]
  • 22.Fang S-C, Huang C-Y, Shao Y-HJ. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia. J Clin Psychiatry. 2022;83(4):21r14153. doi: 10.4088/JCP.21r14153 [DOI] [PubMed] [Google Scholar]
  • 23.Horvitz-Lennon M, Predmore Z, Orr P, Hanson M, Hillestad R, Durkin M, et al. Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. Early Interv Psychiatry. 2019;13(6):1357–65. doi: 10.1111/eip.12770 [DOI] [PubMed] [Google Scholar]
  • 24.Chen W, Xie F, Mccarthy DP, Reynolds KL, Lee M, Coleman KJ, et al. Research data warehouse: using electronic health records to conduct population-based observational studies. JAMIA Open. 2023;6(2):ooad039. doi: 10.1093/jamiaopen/ooad039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zhang Z. Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 2017;5(1):7. doi: 10.21037/atm.2016.08.57 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Polit anal. 2007;15(3):199–236. doi: 10.1093/pan/mpl013 [DOI] [Google Scholar]
  • 27.Chen Y-F, Hemming K, Stevens AJ, Lilford RJ. Secular trends and evaluation of complex interventions: the rising tide phenomenon. BMJ Qual Saf. 2016;25(5):303–10. doi: 10.1136/bmjqs-2015-004372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447–54. doi: 10.1002/sim.4780091208 [DOI] [PubMed] [Google Scholar]
  • 29.Agresti A. Categorical data analysis. John Wiley & Sons; 2012. [Google Scholar]
  • 30.Tukey JW. Exploratory data analysis. Reading/Addison-Wesley; 1977. [Google Scholar]
  • 31.Cohen J. The earth is round (p < .05). American Psychologist. 1994;49(12):997–1003. doi: 10.1037/0003-066x.49.12.997 [DOI] [Google Scholar]
  • 32.Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–8. doi: 10.1002/wps.20699 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–71. doi: 10.1016/S0140-6736(12)60239-6 [DOI] [PubMed] [Google Scholar]
  • 34.Vermeulen J, van Rooijen G, Doedens P, Numminen E, van Tricht M, de Haan L. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017;47(13):2217–28. doi: 10.1017/S0033291717000873 [DOI] [PubMed] [Google Scholar]
  • 35.Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Björkenstam C, Suvisaari J, Alexanderson K, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656–63. doi: 10.1093/schbul/sbu164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Tiihonen J, Tanskanen A, Taipale H. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia. Am J Psychiatry. 2018;175(8):765–73. doi: 10.1176/appi.ajp.2018.17091001 [DOI] [PubMed] [Google Scholar]
  • 37.Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(3 Suppl):13S-21S. doi: 10.1016/0893-133X(95)00200-W [DOI] [PubMed] [Google Scholar]
  • 38.Post RM, Leverich GS, Kupka RW, Keck PE Jr, McElroy SL, Altshuler LL, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry. 2010;71(7):864–72. doi: 10.4088/JCP.08m04994yel [DOI] [PubMed] [Google Scholar]
PLOS Ment Health. doi: 10.1371/journal.pmen.0000731.r001

Decision Letter 0

Jenna Scaramanga

25 May 2026

PMEN-D-26-00108

Long-Acting Injectable Antipsychotics Linked to Reduced Short-Term Disruptive Life Event and Death

PLOS Mental Health

Dear Dr. Han,

Thank you for submitting your manuscript to PLOS Mental Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Mental Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please carefully revise your manuscript to address the points raised by the reviewers.

Please submit your revised manuscript by Jul 20 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at mentalhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pmen/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Jenna Scaramanga

Staff Editor

PLOS Mental Health

Journal Requirements:

1. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

2. We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list.

3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

4. Please provide separate figure files in .tif or .eps format.

For more information about figure files please see our guidelines:  LINK

https://journals.plos.org/mentalhealth/s/figures

https://journals.plos.org/mentalhealth/s/figures#loc-file-requirements

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Does this manuscript meet PLOS Mental Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.-->

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously?-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Mental Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: Review Comments to the Author

This manuscript addresses an important and underexplored topic by examining the association between long-acting injectable antipsychotics (LAIs) and disruptive life events (DLEs) as well as mortality among patients with schizophrenia (SCZ) and bipolar I disorder (BPI). The linkage of electronic health records with external socioeconomic data (e.g., TransUnion records) is innovative and contributes to the growing literature on real-world outcomes in mental health. However, several substantial concerns need to be addressed to improve the scientific rigor, clarity, and interpretability of the findings.

First, while the study objective is clearly stated, the conceptual framing requires strengthening. The manuscript does not sufficiently justify the theoretical or clinical pathways linking LAIs to disruptive life events such as arrests, bankruptcy, and judgment filings. These outcomes are complex and influenced by multiple social, legal, and economic determinants beyond medication adherence. The authors should elaborate a clearer conceptual model explaining how LAIs might plausibly influence such distal outcomes.

Second, the methodological limitations are significant and require more transparent acknowledgment and handling. The very small sample size in the LAI arm (n=218) and extremely low number of outcome events (only two DLE events in the LAI group) severely limit statistical power and the reliability of the findings. Although the authors acknowledge this, the implications are not fully reflected in the interpretation. The use of p<0.10 as a threshold for statistical significance is also questionable and should be more strongly justified or avoided, as it increases the risk of Type I error.

Third, there are concerns regarding potential selection bias and confounding. The observational design and non-random allocation to LAI versus oral treatment introduce strong risks of confounding by indication. Although propensity score matching was used, the matching variables appear limited (e.g., no inclusion of illness severity, comorbidities, socioeconomic status, or prior adherence behavior). This raises concerns about residual confounding that may bias the results.

Fourth, the definition of exposure (LAI use within 180 days post-index event) may introduce misclassification bias. Patients in the LAI arm also received oral antipsychotics, which complicates attribution of effects solely to LAIs. A more nuanced exposure definition or sensitivity analyses (e.g., timing, duration, or exclusive LAI use) would strengthen the analysis.

Fifth, the outcome measures—particularly DLEs derived from credit and legal records—require further clarification. The validity, completeness, and potential biases in linking TransUnion data to clinical records should be discussed in greater detail. Additionally, the ethical implications of using such data sources should be explicitly addressed.

Sixth, the generalizability of the findings is limited. The study population is relatively young (mean age ~22 years), drawn from a single integrated healthcare system, and has low Medicaid representation. These factors should be more critically discussed in relation to broader populations with SCZ and BPI.

Seventh, the interpretation of results tends to overstate the findings. The conclusions suggest that LAIs “may improve” outcomes, yet the results are largely non-significant and based on extremely sparse data. The language should be revised to reflect the exploratory nature of the study and the high level of uncertainty.

Finally, issues related to research and publication ethics should be clarified. Although funding sources are disclosed, the involvement of funders in study design and manuscript preparation raises potential concerns about bias and should be discussed more transparently. The data availability statement also does not fully align with PLOS policies, as the data are not publicly accessible; the authors should provide a clearer justification and indicate whether data access can be granted under reasonable conditions.

Summary Recommendation

The manuscript addresses a novel and relevant research question with an innovative dataset. However, major revisions are required to address concerns related to conceptual framing, methodological rigor, statistical validity, interpretation of findings, and transparency. Strengthening these areas will significantly improve the manuscript’s contribution to the field.

Reviewer #2: Thank you for the opportunity to review this paper. I would like to acknowledge the effort and commitment of the authors in addressing an important and complex topic. While the study presents interesting findings, I have several concerns that I believe should be addressed to strengthen the work.

My primary concern relates not only to what is included in the study, but also to what appears to be excluded. First, LAI antipsychotics are not clearly defined in terms of duration of action, administration protocols, or care processes. Greater clarity is needed regarding how long these injections last, how frequently they require clinical oversight, and where and how they are typically administered. Given that the study focuses on short-term outcomes, it would also be important to clearly outline, if not all, but some of the short-term side effects associated with LAIs.

Relatedly, the method of administration is a significant omission. In many cases, particularly in the context of psychosis, injectable antipsychotics may be administered involuntarily. If this occurred within the study population, factors such as coercion or hospitalization could themselves influence disruptive life events (DLEs), yet these variables are not accounted for in the analysis. Although the current research landscape offers limited means of systematically capturing these dynamics, their omission should be explicitly acknowledged, as they may meaningfully shape the outcomes reported.

More broadly, the study does not appear to incorporate patient perspectives, which represents a notable limitation. By focusing primarily on clinical outcomes and narrowly defined DLEs, the research may overlook how patients themselves experience and interpret the impact of LAI treatment. Given the study design, patient perspectives may not be feasible to include; however, this should also be more explicitly acknowledged as a limitation, as their absence restricts a more balanced understanding of the findings.

Although the study is concerned with short-term outcomes, some contextual reference to the longer-term effects of antipsychotic treatment would be valuable. There is an increasing emphasis in the literature on the potential harms associated with psychotropic medications, and acknowledging this would help situate the findings more comprehensively and with greater balance.

I am also concerned about potential misrepresentation in the introduction. The statement that “many patients and mental health care providers were found to have somewhat unfavorable perceptions of LAIs” appears to rely on a study that included a limited sample, including 25 psychiatrists. While the findings may reflect the perspectives within that study, the phrasing risks overstating or generalizing these views. Greater precision in how this evidence is presented would improve accuracy. Additionally, the same referenced study discusses the “coercive image” of LAIs, which further underscores the importance of addressing how these medications are administered. An issue not sufficiently explored in the current paper.

Finally, there are broader ethical considerations worth noting. The use of personal and health records, while valuable for observational research, inherently excludes subjective patient experiences that cannot be captured through quantitative data alone. Furthermore, the classification of DLEs (e.g., arrests, bankruptcy, judgments) raises questions about how these categories were selected and whether they adequately account for broader social and structural determinants of health. Without this context, there is a risk of reinforcing stigma associated with severe mental illness.

In summary, while the study addresses an important area, there is considerable scope for expansion and refinement. Greater clarity, contextualization, and reflexivity, particularly regarding methodology, interpretation, and ethical considerations, would significantly strengthen the paper.

I hope these comments are received in the constructive spirit in which they are intended, and I appreciate the opportunity to engage with this work.

Reviewer #3: Great study that will add much to the decision of clinicians whether to use LAI or not.

The structure of the article is logical, with each section building upon the previous one, making it easy for readers to understand the progression of ideas. This is an informative article that I believe it will contribute well to the field.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review?  If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

-->Figure Resubmissions:

-->-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->-->

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.-->

PLOS Ment Health. doi: 10.1371/journal.pmen.0000731.r003

Decision Letter 1

Jenna Scaramanga

2 Sep 2026

Long-Acting Injectable Antipsychotics Linked to Reduced Short-Term Disruptive Life Event and Death

PMEN-D-26-00108R1

Dear Dr. Han,

We are pleased to inform you that your manuscript 'Long-Acting Injectable Antipsychotics Linked to Reduced Short-Term Disruptive Life Event and Death' has been provisionally accepted for publication in PLOS Mental Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact mentalhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Mental Health.

Best regards,

Karli Montague-Cardoso

Staff Editor

PLOS Mental Health

***********************************************************

Reviewer Comments (if any, and for reference):

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: point by point response.docx

    pmen.0000731.s001.docx (25.4KB, docx)

    Data Availability Statement

    The individual-level data underlying this study cannot be made publicly available because they contain protected health information and are subject to institutional and third-party data-use agreements that prohibit public disclosure. Qualified researchers may request access to the data. Access is subject to institutional review, approval of the proposed use, and execution of applicable data-use agreements. Kaiser Permanente Southern California Institutional Review Board (https://kpscnursingresearch.org/kpsc-institutional-review-board-irb/) can be contacted by email (Regina.M.Valdez@kp.org).


    Articles from PLOS Mental Health are provided here courtesy of PLOS

    RESOURCES